Remarkable Effect of Metronomic Chemotherapy in Diffuse Lung Metastases of Thyroid Cancer

Criel M and Geurs F*
Medical Oncology, Sint-Maria Ziekenhuis, Halle, Belgium

Abstract
We present a patient with respiratory insufficiency due to progressive lung metastases of thyroid cancer. Low dose i.v. vinblastin, oral cyclophosphamide and s.c. enoxaparin produced dramatic clinical improvement, a drop in thyroglobulin and prolonged disease stabilisation. This new way of giving classical chemotherapy is called metronomic chemotherapy. Its anti-angiogenic basis of activity is corroborated by the more recent drugs in thyroid cancer which share this mechanism.

Introduction
Until recently, there was no effective chemotherapy for iodine refractory thyroid cancer. The use of lower dose chemotherapy (called “metronomic chemotherapy”) like in other endocrine responsive tumors was never evaluated in this tumor type. The clinical benefit, as well as the prolonged disease stabilisation by metronomic chemotherapy in a palliative patient with massive lung metastases, illustrates empirically the anti-angiogenic effect of this type of chemotherapy. It predates the recent avalanche of specific angiogenesis inhibitors in this disease.

Case Presentation
Our patient first presented at the age of 55 with a large mediastinal mass in 2000. After resection this proved to be a follicular thyroid adenocarcinoma weighing 270 grams. Postoperatively, he received a first dose of radioactive iodine (Iγ) at a dosage of 100 mCi. In 2003 two doses of 100 mCi each were given for an asymptomatic rise in thyroglobulin. In 2004 a local lymph node recurrence was detected and resected. That time lung metastases were documented on imaging. These were treated with one dose of 150 mCi of Iγ. A rise in thyroglobulin and increase in size of lung metastasis were treated with two doses of 150 mCi Iγ in 2005.

In 2008 there was an increase of the lung metastases on PET-scan and chest x-ray. Although most lung metastases didn’t show any further iodine uptake, indicating iodine resistance, a final dose of 150 mCi was nevertheless administered. The re-evaluation three months later showed further progression of the lung metastasis and a further increase of serum thyroglobulin to 90.500 ng/ml on 10/11/2008. The patient, then 63 years, was therefore referred to a tertiary cancer center to start sorafenib in a compassionate use programme.

During the following eighteen months, the patient was treated with two doses of 150 mCi Iγ in 2008. Unfortunately this protocol was closed and the patient was treated to participate in a phase II trial with a new tyrosine kinase inhibitor. In October 2011, after 24 months of treatment, progression was documented by a rise in thyroglobulin over 200 000 ng/ml and a slight increase in lung lesions (Figure 3). The patient was therefore referred to a tertiary cancer center to start sorafenib in a compassionate use programme.

*Corresponding author: Filip Geurs, Reg Zh Sint Maria, Ziekenhuislaan 100, Halle, Vl Brabant, 1500, Belgium, Tel: 32-2363-6610; E-mail: g@regzhsintmaria.be

Received November 04, 2011; Accepted February 03, 2012; Published February 06, 2012

Citation: Criel M, Geurs F (2012) Remarkable Effect of Metronomic Chemotherapy in Diffuse Lung Metastases of Thyroid Cancer. Thyroid Disorders Ther 1:101. doi:10.4172/2167-7948.1000101

Copyright: © 2012 Criel M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Discussion

Thyroid carcinoma is the most common malignancy of the endocrine system, and the vast majority of these carcinomas are of the papillary or follicular subgroups. The majority of these well-differentiated thyroid carcinomas (DTCs) are highly treatable by surgery, followed in most patients by $^{131}$I and TSH-suppressive doses of levothyroxine [1]. Indeed, the overall 10-yr survival rate is 93% for patients with papillary thyroid carcinoma (PTC) and 85% for patients with follicular thyroid carcinoma (FTC). However, about 2% of patients with PTC and 6% of those with FTC or Hurthle cell carcinoma have distant metastases at the time of diagnosis [2], and an additional group of patients develop identifiable distant metastases during long-term follow-up [3,4]. The long-term disease-specific survival of patients with either DTC with distant metastases is less than 50% at 5 yr [2,4,5]. Furthermore, a subgroup of these patients with distant metastases, including those with metastases that concentrate $^{131}$I poorly, have brain, bone, or large lung metastases or bulky fluoro deoxyglucose-avid metastases [6-8] that typically do not respond to $^{131}$I therapy.

Alternative systemic treatments for widely metastatic DTC using cytotoxic chemotherapy have been of limited utility. Until recently, chemotherapy for metastatic radio-iodine refractory thyroid cancer was limited to anthracyclines and some case reports [9]. This has recently changed with the advent of efficient targeted therapies [10] initially in medullary thyroid cancer and subsequently also in papillary and follicular cancer. These targeted treatments essentially block intracellular pathways or have anti-angiogenic properties.

Comprehensive studies of mutation pathways in DTC and MTC have been undertaken in the past two decades [11,12]. The knowledge gained from these analyses made DTC and MTC amenable to designer
therapeutics. The most important findings centre on the discovery of oncogenic kinases, as well as the elucidation of various signalling pathway adaptations occurring in malignant cells. Of the oncogenic kinases, BRAF V600E mutation and RET/PTC mutations are being targeted as potential pathways for therapeutic intervention. Both of these mutations have the potential to activate the mitogen-activated protein kinase (MAPK) pathway downstream [10].

The BRAF inhibitor studied most in thyroid cancer is sorafenib. Sorafenib is an oral tyrosine kinase inhibitor. A number of phase II trials of sorafenib involved advanced or metastatic DTC. These patients’ tumors demonstrated partial responses in 15–27% of participants, and stable disease in a little over 34–61% [13-15].

Sunitinib is a tyrosine kinase inhibitor affecting VEGFR 1/2/3, RET, RET/PTC1. Of DTC and MTC patients enrolled in a phase II trial of sunitinib receiving 50 mg/day, partial response was observed in 13% of patients with DTC, while stable disease was the best response in 68% of patients with DTC [16,17].

Other important signalling cascades being investigated for the possible development of therapeutic kinase inhibitors are the VEGF and PDGF pathways. VEGF is a pro-angiogenic factor that binds to two receptor tyrosine kinases (VEGFR-1 and VEGFR-2), of which VEGFR-2 is widely recognized to be the primary mediator of angiogenesis. PDGF-B is required for the maturation of microvasculature, while tumor-derived PDGF-A recruits angiogenic stroma to the tissue. VEGFR and PDGFR mutually support the increased activity of each other [18]. Increased VEGF expression appears to be related to worse prognosis, increased risk of recurrence, and the presence of metastasis [19].

Pazopanib is a second-generation oral small molecule kinase inhibitor that targets VEGFR-1, 2, and 3, as well as alpha and beta PDGFR [20]. A phase II study completed in early 2009 of thyroid cancer patients led by the Mayo Clinic demonstrated a confirmed partial response rate by RECIST criteria in 49% of enrolled subjects (18 patients).

Motesanib is an oral tyrosine-kinase inhibitor. It demonstrates both direct antitumor and anti-angiogenic properties [21]. Phase I trials were encouraging with 3 DTC patients registering a partial response [22]. A subsequent phase II trial administering 125 mg/day to patients with DTC demonstrated a partial response in 14% of patients, while 35% of patients had stable disease after 48 weeks [23].

All these newer drugs underline the importance of angiogenesis in thyroid cancer and its inhibition by blocking the VEGF-R. It is therefore logical that classical chemotherapy, with the mainly cytotoxic activity, showed little effect.

A more recent way of giving chemotherapy, called “metronomic chemotherapy”, has also important anti-angiogenic properties by blocking endothelial proliferation [24]. It has proven efficacy in endocrine sensitive tumors like prostate cancer and breast cancer. Partial responses and disease stabilizations were obtained with prolonged administration of cyclophosphomide [25-27]. Thyroid cancer was never before treated with this way of prolonged chemotherapy. Angiogenic inhibition by chemotherapy has therefore not been explored in these rare tumors. The success in our patient on symptom control and decrease in thyroglobulin rests on the unique method of activity of this particular administration of chemotherapy. By using low dose cyclophosphomide orally and weekly vinblastin, we applied a regimen with maximal anti-angiogenic properties as demonstrated in several prior publications [28,29]. We also applied the antitumoral effect of enoxaparin in this regimen, which works by inhibition of tumor cell adhesion [30]. This led to an initial decrease in thyroglobulin and prolonged disease stabilisation exceeding 18 months, as can be seen in the most promising of all recent anti-VEGF-R inhibitors.

Conclusion

This is the first case report on the clinical benefit of metronomic chemotherapy in diffuse lung metastases of thyroid cancer. This type of chemotherapy works by an antiangiogenic mechanism and thus, this case report confirms the common pathway with the more recent drugs developed for thyroid cancer.

References

1. Schlumberger MJ (1998) Papillary and follicular thyroid carcinoma. N Engl J Med 338: 297-306.
2. Hundahl SA, Fleming ID, Fremgen AM, Mertlik HR (1998) A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see comments]. Cancer 83: 2638-2648.
3. Schlumberger M, Challeton C, De Vathaire F, Travaglin JP, Gardet P, et al. (1996) Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 37: 598-605.
4. Woyach JA, Kloos RT, Ringel MD, Arbogast D, Collamore M, et al. (2009) Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab 94: 164-170.
5. Shaha AR, Shah JP, Loree TR (1997) Differentially expressed thyroid cancer presenting initially with distant metastasis. Am J Surg 174: 474-476.
6. Schlumberger M J (1999) Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status. J Endocrinol Invest 22: 3-7.
7. Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, et al. (2006) Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91: 498-505.
8. Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, et al. (2000) Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 85: 1107-1113.
9. Sherman SI (2010) Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol) 22: 464-468.
10. Bales SR, Chopra IJ (2011) Targeted treatment of differentiated and medullary thyroid cancer. J Thyroid Res 2011: 102636.
11. Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, et al. (2006) BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 12: 1623-1629.
12. Ciampi R, Nikiforov YE (2007) RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 148: 936-941.
13. Gupta-Abraham S, Troxel AB, Nellore A, Pultaswamy K, Redlinger M, et al. (2008) Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26: 4714-4719.
14. Kloos RT, Ringel MD, Knopf MV, Hall NC, King M, Stevens R, et al. (2009) Phase II trial of sorafenib in metastatic thyroid carcinoma. J Clin Oncol 27: 1675-1684.
15. Hoffjizer J, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, et al. (2009) Beneficial effects of sorafenib on tumor progression, but not on radioliodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 161: 923-931.
16. Carr LL, Makoff DA, Goulart BH, Eaton KD, Capel PT, et al. (2010) Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 16: 5260-5268.

17. Bugalho MJ, Domingues R, Borges A (2009) A case of advanced medullary thyroid carcinoma successfully treated with sunitinib. Oncologist 14: 1083-1087.

18. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438: 967-974.

19. Klein M, Vignaud JM, Hennequin V, Toussaint B, Bresler L, et al. (2001) Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 86: 656-658.

20. Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, et al. (2007) Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multitarget angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 6: 2012-2021.

21. Polverino A, Coxon A, Starnes C, Diaz Z, DeMeffe T, Wang L, et al. (2006) AMG 706, an oral, multitarget inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 66: 8715-8721.

22. Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, et al. (2007) Safety, pharmacokinetics, and efficacy of AMG 706, an oral multitarget inhibitor, in patients with advanced solid tumors. J Clin Oncol 25: 2369-2376.

23. Sherman SI, Wirth LJ, Druzz JP, Hofmann M, Bastholt L, et al. (2008) Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359: 31-42.

24. Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4: 423-436.

25. Bocci G, Tucci M, Emmenegger U, Liguori V, Falcone A, et al. (2005) Cyclophosphamide-methotrexate ‘metronomic’ chemotherapy for the palliative treatment of metastatic breast cancer: A comparative pharmacoeconomic evaluation. Ann Oncol 16: 1243-1252.

26. Licchetta A, Corseale P, Migali C, Remondo C, Francini E, et al. (2010) Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate. J Chemother 22: 201-204.

27. Greiner J, Küfer R, Reske SN, Martin V, Döhnner H, et al. (2010) Metronomic treatment with low-dose trofosfamide leads to a long-term remission in a patient with docetaxel-refractory advanced metastatic prostate cancer. Case Report Med.

28. Young SD, Whissell M, Noble JC, Cano PO, Lopez PG, et al. (2006) Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors. Clin Cancer Res 12: 3092-3098.

29. Wong NS, Buckman RA, Clemons M, Verma S, Dent S, et al. (2010) Phase II trial of metronomic chemotherapy with daily dailteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. J Clin Oncol 28: 723-730.

30. Robert F (2010) The potential benefits of low-molecular-weight heparins in cancer patients. J Hematol Oncol 3: 3.